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S200 Poster Session Iof 2-year survival. Summary data regarding histologic subtype,
stage, immune status, viral load at ASCT and conditioning regi-
men will also be presented.
Conclusion: ASCT for HIV(+) patients has a comparable response
and survival to the HIV(-) population for ASCT. Consideration of
ASCT as an earlier therapeutic option in HIV related lymphoma
should be investigated. Additional prospective trials are necessary
to determine optimal management of this population.115
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Introduction: PB CD34+ cells are routinely monitored to optimize
the timing and success of CD34+ stem cell collection after G-CSF6
chemotherapy mobilization in NHL patients (pts) undergoing auto-
HSCT.A threshold of#10PBCD34+cells/ml is oftenused topredict
poor mobilization and aid the decision of whether novel therapies
such as plerixafor should be included in the mobilization scheme.
This analysis evaluatedwhether a PB threshold#10 cells/ml is indeed
the most optimal threshold to predict mobilization failure.
Methods:This was a post-hoc analysis of pts with NHL (enrolled in
the phase 3 study 3101) mobilized with G-CSF alone (10 mg/kg SC
for up to 8 doses). PB CD34+ cells were measured on the morning of
Day 4,24H prior to apheresis. The proportion of pts collecting the
minimal ($2  106) or optimal ($5  106) CD34+ cell dose and
apheresis yields were evaluated in pts with PB CD34+ cells/ml #10
(PB #10) or .10 (PB .10).
Results: This analysis was restricted to patients randomized to re-
ceive G-CSF plus placebo. In the 3101 study, 142 pts were mobi-
lized with G-CSF alone; Day 4 PB CD34 cell counts were available
for 124 pts. 75/124 (60%) pts had PB #10 and 49/124 (40%) pts
had PB .10. The median CD34+ cell yield in 2 days was 0.97 
106 cells/kg in pts with PB #10 and 3.3  106 cells/kg in pts
with PB .10. The median CD34+ cell yield in 4 days was 1.31
 106 cells/kg in pts with PB #10 and 4.52  106 cells/kg in pts
with PB .10. Only 22.7% pts with PB #10 and 65.3% pts with
PB .10 collected the minimal cell dose of $2 x106 cells/kg in 2
days. If apheresis was continued for 4 days then 34.7% pts with
PB #10 and 79.6% pts with PB .10 were able to collect the min-
imal dose. Similarly, only 5.3% pts with PB #10 and 30.6% pts
with PB .10 collected the optimal cell dose of $5 x106 cells/kg
in 2 days. Continuing apheresis for 4 days allowed 10.7% patients
with PB #10 and 40.8% patients with PB .10 to collect the opti-
mal dose.
Conclusion:Collectively, these data demonstrate that if apheresis
was planned in pts with .10 PB CD34+ cells/ml, then 20.4% pts
would not collect the minimal cell dose ($2106) and 59.2% pts
would not collect the optimal cell dose ($5106) in 4 apheresis
days. Thus, a threshold of .10 PB CD34+ cells/ml does not en-
sure adequate stem cell collection in a significant proportion of
NHL patients mobilized with G-CSF alone. Higher PB
CD34+ thresholds should be evaluated to ensure effective HSC
collection in NHL pts proceeding to HSCT.
Mobilization Outcomes in G-CSF Mobilized Patients with PB
#10 or PB. 10Median (range) cumulative CD341 cells/
kg x 106 after 2 apheresis days0.97 (0.06 - 9.16) 3.30 (0.46 - 12.00)Median (range) cumulative CD341 cells/
kg x 106 after 4 apheresis days1.31 (0.06 - 10.58) 4.52 (0.46 - 15.00)% Pts achieving $2 x 106 CD341Cells/
Kg in 2 days22.7 65.3% Pts achieving $2 x 106 CD341Cells/
Kg in 4 days34.7 79.6% Pts achieving $5 x 106 CD341Cells/
Kg in 2 days5.3 30.6% Pts achieving $5 x 106 CD341Cells/
Kg in 4 days10.7 40.8116
ADDITION OF BORTEZEMIB TO HIGH DOSE MELPHALAN DOES NOT IM-
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Background: High dose melphalan remains the preparative regi-
men of choice for autologous hematopoietic stem cell transplan-
tation (auto HCT) in multiple myeloma (MM). Bortezomib is
an active agent in newly diagnosed or relapsed MM, and has syn-
ergistic activity with melphalan. We recently conducted two ran-
domized phase II trials in MM, one of which studied the safety
and efficacy of adding bortezomib to high-dose melphalan in
the preparative regimen for auto HCT. Here we report the re-
sponse rates, progression-free survival (PFS) and overall survival
(OS) between the melphalan-based preparative regimens with or
without bortezomib.
Methods: In the first randomized trial 48 patients received high-
dose Melphalan at 100 mg/m2 IV on days -4 and -3, and ascorbic
acid (AA) 1000 mg IV daily on days -9 to -3. Patients in arm 1
did not receive arsenic trioxide (ATO); patients in arm 2 received
ATO 0.15 mg/kg IV from days -9 to -3; patients in arm 3 re-
ceived ATO at 0.25 mg/kg from days -9 to -3. In the second ran-
domized trial 60 patients were enrolled and 58 received an auto
HCT with a preparative regimen of melphalan 100 mg/m2 IV on
days -4 and -3, AA 1000 mg/day IV on days -9 to -3 and ATO
0.25 mg/kg IV on days -9 to -3. Patients in the second trial were
randomized to 3 arms; no bortezomib (arm 1), bortezomib 1 mg/
m2 on days -9, -6 and -3 (arm 2), and bortezomib 1.5 mg/m2 on
days -9, -6 and -3 (arm 3).
Results: A total of 106 patients received an auto HCT in these 2
trials. Of 106 patients, 39 received a preparative regimen with
bortezomib (Group A) and 67 without bortezomib (Group B). Pa-
tient characteristics and outcome are summarized in Table 1. Pa-
tients in group B (without bortezomib) were slightly older, had
a longer interval between diagnosis and auto HCT and 21%
had a prior auto HCT (vs. 2% in group A). Complete + very
good partial response rates (CR + VGPR) in groups A and B
were similar (31% vs. 31%). Median PFS and OS in group A
vs. B were 14 vs. 23 months (p5 0.08) and 80 vs. 82 months
(p5 0.17), respectively.
Conclusions: In this analysis of 106 patients, adding bortezomib to
a HD melphalan preparative regimen did not improve the response
rate, PFS or OS.
Patient Characteristics and Outcomes
Group A Group B
(Bortezomib) (No Bortezomib)Number of patients 39 67
Median age 59 55
Abnormal cytogenetics 13 11
Relapsed disease 10 25
Prior auto HCT 1 14
Months from diagnosis to auto HCT 9 14
Median CD34 dose 106/kg 3.9 4.56
Median days to engraftment 10 10
Grade 3-4 adverse effects 12 20
CR 7 (18%) 16 (24%)(Continued )
Poster Session I S201. (Continued )
PG (n5 38) OTH (n5 58) P
Number of aphereses; median 2 (1-4) 3 (1-5) 0.12
Group A
(Bortezomib)
Group B
(No Bortezomib)
(range)
Total CD341 cells collected 2.09 1.42 0.003CR1VGPR 12 (31%) 22 (31%)
(x106/kg); median (range)Median PFS (months) 14 23Number of patients collecting 14 (37%) 1 (2%) \0.0001Median OS (months) 80 82
2 million CD341 cells in
one apheresis# clinic visits (MD/PA) 2 (0-6) 1 (0-9) 0.15
# days IV antibiotics 0 (0-7) 0 (0-14) 0.1
# inpatient days 0 (0-4) 0 (0-13) 0.02
# RBC units transfused 0 (0-6) 0 (0-11) 0.22
Platelet units transfused 0 (0-24) 0 (0-36) 0.6
# of CBC/diff performed 7 (3-15) 7 (2-27) 0.26
# of comprehensive metabolic
panels performed
2 (0-6) 2 (0-19) 0.94117
LONG TERM SURVIVAL FOLLOWING HIGH DOSE SEQUENTIAL CHEMO-
THERAPYWITH AUTOLOGOUS HEMATOPOIETIC CELL RESCUE FORMUL-
TIPLE MYELOMA
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Sullivan, K.1, Edwards, J.2, Jacobson, R.3, Corbet, K.1, Chao, N.1,
Long, G.1 1Duke University Medical Center, Durham, NC; 2Florida
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High-dose therapy (HDT) with autologous hematopoietic cell
rescue (AHCR) improves survival in patients with multiple mye-
loma, but is not curative due to a continuous risk of relapse.
One approach to try to reduce relapse is to optimize pretransplant
therapy and the preparative regimen. We investigated the out-
come of sequential HDT with AHCR. Patients were initially
treated with standard dose chemotherapy (primarily VAD) to
maximum response. They then received cyclophosphamide 4
gm/m2 followed by G-CSF and peripheral blood hematopoietic
cell collection by apheresis upon count recovery. They were
then treated with etoposide 2 gm/m2 followed by G-CSF and
apheresis upon count recovery. The transplant preparative regi-
men consisted of carmustine 500 mg/m2 on day -4 and melphalan
200 mg/m2 on day -2 followed by AHCR on day 0. Seventy-six
patients were treated between 1997 and 2001. The patient popu-
lation included 56% males with a median age at transplant of 54
years (range 39-68 years). Forty patients had IgG myeloma, 11 pa-
tients had IgA myeloma, 8 patients had light chain only disease, 5
patients had nonsecretory disease, 1 patient had IgM myeloma and
subtype is unknown in 11 patients. Forty patients were trans-
planted with CD34 selected cells. The Kaplan-Meir estimated me-
dian progression-free survival is 4.2 years (CI 3.1-6.0 years) with
a median overall survival of 7.2 years (CI 4.8-11.4 years). The me-
dian follow up of the 36 surviving patients is 8.46 years with
a range of 4.71 to 11.4 years. One patient was lost to follow up.
The Kaplan-Meir estimated progression-free survival at 10 years
is 35% with overall survival of 45%. Two patients died of inter-
stitial pneumonitis at 21 and 76 days post transplant and two pa-
tients died of secondary leukemia at 694 and 712 days post
transplant. High dose sequential chemotherapy is well tolerated
and results in long term survival in a significant proportion of pa-
tients with multiple myeloma.118
RETROSPECTIVE COMPARISON OF SECONDARY MOBILIZATION STRATE-
GIES IN CANDIDATES FOR AUTOLOGOUS HEMATOPOIETIC CELL TRANS-
PLANTION WITH A FOCUS ON RESOURCE UTILIZATION:
PLERIXAFOR + G-CSF VERSUS OTHER REGIMENS
Perkins, J., Bookout, R., Sapiro, J., Alsina, M., Ayala, E., Field, T.L.,
Kharfan-Dabaja, M.A., Perez, L.E., Ochoa-Bayona, J.L.,
Tomblyn, M., Daily, K., Elstner, C., Anasetti, C., Fernandez, H.F. Mof-
fitt Cancer Center, Tampa, FL
Successful autologous transplantation relies on hematopoietic cell
mobilization that allows adequate CD34+ cell collection. Depite ap-
propriate mobilization approaches, a significant number of patients
(pts) do not mobilize adequate CD34+ cells and require a second
round of mobilization therapy. We performed a retrospective analy-
sis of our experience with different secondary mobilization strategies
with a focus on resource utilization. Primary endpoint was compar-ing plerixafor versus other regimens with respect to the rate of suc-
cessful second mobilization defined as the ability to collect at least
2106 CD34+ cells/kg (cumulative). Included here are 96 pts receiv-
ing their primary mobilization therapy between 2000-09. Pts are di-
vided into two groups depending on the secondary mobilization
therapy given: Plerixafor + G-CSF (PG; n5 38) or Other (OTH;
n5 58). which included chemotherapy +G-CSF in 15 pts, G-CSF
alone in 23 pts or G-CSF andGM-CSF in 20 pts. There were no dif-
ferences in pt characteristics between the two groups except for
a higher number of non-Hodgkin’s lymphoma pts in the PG group
and more pts with multiple myeloma in the OTH group. In the
PG mobilized group, 29% were first mobilized with chemothera-
py +G-CSF and 71% were mobilized with G-CSF alone. In the
OTH pts, 41% received chemotherapy +G-CSF, 43% G-CSF
alone, and 16% G-CSF +GM-CSF. Median numbers of CD34+
cells (x 106/kg) collected after the first mobilization were 0.39 (0-
1.76) in the PG pts and 0.56 (0-2.08) in the OTH pts. Pts in the
PG group received a median of 2 doses of plerixafor (range 1-4) dur-
ing their second mobilization regimen. Eight of the 38 PG pts were
enrolled on clinical trials requiring at least 2 doses of plerixafor and
a minimum of 2 aphereses. Outcomes following the second mobili-
zation and resource utilization from the first day of second
mobilization to the last day of pheresis are shown below. Thirty-
two of the 38 PG pts (84%) were able to collect a total of at least 2
 106 CD34+ cells/kg from both mobilizations to proceed to trans-
plant; this is compared to 47/58 (80%) in theOTHgroup (p5 0.62).
Of those pts that were transplanted, there were no differences in time
to neutrophil or platelet recovery. The current data suggest that
when using plerixafor plus G-CSF in this setting there is a potential
for significant cost savings based on the reduced apheresis and hos-
pitalization requirements when compared to other forms of mobili-
zation.119
QUALITY OF UMBILICAL CORD BLOODUNITS STORED FOR AUTOLOGOUS
USE AND INFUSED INTRAVENOUSLY IN CHILDREN WITH ACQUIRED
NEUROLOGICAL CONDITIONS
Sun, J., Allison, J., McLaughlin, C., Sledge, L., Waters-Pick, B.,
Kurtzberg, J. Duke University, Durham, NC
Background: Numerous animal models demonstrate neurological
and survival benefits of bone marrow or umbilical cord blood (CB)
infusion in the setting of stroke, thermal injury, ischemia, intracra-
nial hemorrhage and spinal cord injury. Based on these data, we ini-
tiated a pilot study to determine the safety and feasibility of
intravenous (IV) administration of autologous CB (aCB) in young
children with acquired neurological disorders. Most units were elec-
tively stored in private CB banks at the request and expense of the
